Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval of TRYNGOLZA for Severe Hypertriglyceridemia and Acute Pancreatitis Risk Reduction June 24, 2026 3:30 PM EDT
Company Participants
D. Walke - Senior Vice President of Investor Relations
Brett Monia - Founder, CEO & Director
Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development
Kyle Jenne - Executive VP & Chief Global Product Strategy Officer
Conference Call Participants
Steven Ionov - TD Cowen, Research Division
Yanan Zhu - Wells Fargo Securities, LLC, Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Michael Ulz - Morgan Stanley, Research Division
Jason Gerberry - BofA Securities, Research Division
Jasmine Fels - Barclays Bank PLC, Research Division
Gary Nachman - Canaccord Genuity Corp., Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Eric Joseph - Citigroup Inc., Research Division
Myles Minter - William Blair & Company L.L.C., Research Division
Presentation
Operator
Good afternoon, and welcome to Ionis' conference call to discuss the FDA approval of TRYNGOLZA for sHTG. As a reminder, note that this conference call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Wade, please begin.
D. Walke
Senior Vice President of Investor Relations
Thank you, Sylvie, and thank you to everyone who has joined us today as we discuss the FDA approval of TRYNGOLZA for sHTG, which is now approved in the U.S. to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. Please be sure to visit the Investors section of the Ionis website to see the press release and Ionis issued -- press release that Ionis issued earlier today, along with the slides accompanying today's webcast.
Before we begin, I would like to remind you that our discussion today will contain forward-looking statements based on our
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。